Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin

Ann Intern Med. 2022 Dec;175(12):W155. doi: 10.7326/L22-0333.

Authors

HoJin Shin¹, Sebastian Schneeweiss², Robert J Glynn¹, Elisabetta Patorno¹

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 36534995
DOI: 10.7326/L22-0333

No abstract available

Publication types

Comment

MeSH terms

Cardiovascular Diseases* / chemically induced
Diabetes Mellitus, Type 2*
Glucose
Humans
Hypoglycemic Agents
Metformin*
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Metformin
Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents
Glucose
Sodium